Intellia Therapeutics (NASDAQ:NTLA) Trading Up 10.1% - Still a Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) traded up 10.1% during trading on Monday . The company traded as high as $7.83 and last traded at $7.96. 607,328 shares changed hands during trading, a decline of 74% from the average session volume of 2,343,039 shares. The stock had previously closed at $7.23.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. StockNews.com raised Intellia Therapeutics to a "sell" rating in a research report on Monday, March 3rd. The Goldman Sachs Group restated a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Morgan Stanley cut Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. Truist Financial reduced their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Wedbush restated a "neutral" rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $36.68.

Intellia Therapeutics Stock Performance

The firm has a market capitalization of $843.66 million, a PE ratio of -1.50 and a beta of 2.23. The firm's 50 day moving average price is $8.89 and its 200-day moving average price is $12.11.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Ensign Peak Advisors Inc increased its holdings in Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after acquiring an additional 1,100 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after purchasing an additional 1,538 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock valued at $157,000 after buying an additional 1,582 shares in the last quarter. Arizona State Retirement System boosted its holdings in Intellia Therapeutics by 6.1% in the 4th quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock worth $327,000 after buying an additional 1,615 shares during the last quarter. Finally, E Fund Management Co. Ltd. lifted its position in shares of Intellia Therapeutics by 10.0% in the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after acquiring an additional 1,634 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.